[{"orgOrder":0,"company":"DelSiTech","sponsor":"DelSiTech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"DelSiTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"DelSiTech \/ DelSiTech Ltd","highestDevelopmentStatusID":"4","companyTruncated":"DelSiTech \/ DelSiTech Ltd"},{"orgOrder":0,"company":"DelSiTech","sponsor":"IVERIC bio","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","graph1":"Ophthalmology","graph2":"Phase III","graph3":"DelSiTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Sustained-Release","sponsorNew":"DelSiTech \/ DelSiTech","highestDevelopmentStatusID":"10","companyTruncated":"DelSiTech \/ DelSiTech"},{"orgOrder":0,"company":"DelSiTech","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"DelSiTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"DelSiTech \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"DelSiTech \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"DelSiTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"DST-2105","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"DelSiTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"DelSiTech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"DelSiTech \/ Not Applicable"},{"orgOrder":0,"company":"DelSiTech","sponsor":"DRW Venture Capital LLC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Entecavir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DelSiTech","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"DelSiTech \/ DRW Venture Capital LLC","highestDevelopmentStatusID":"1","companyTruncated":"DelSiTech \/ DRW Venture Capital LLC"}]

Find Clinical Drug Pipeline Developments & Deals by DelSiTech

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Proceeds will support clinical development of DST1308, using a silica-based drug delivery platform, for Chronic Hepatitis B.

                          Brand Name : DST1308

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 16, 2024

                          Lead Product(s) : Entecavir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : DRW Venture Capital LLC

                          Deal Size : $10.8 million

                          Deal Type : Financing

                          blank

                          02

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : DST-2105 is based on DelSiTech's Silica Matrix formulation technology which enables the once daily administration of eye drops in the cul-de-sac of the eye, which is investigated for relieving dry eye symptoms.

                          Brand Name : DST-2105

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 29, 2023

                          Lead Product(s) : DST-2105

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : DelSiTech will develop long-acting injectable formulations ensuring slow release of HIV vaccine. Silica Matrix technology provides controlled long-acting drug release w/o interfering with its therapeutic functions and is compatible with small molecules a...

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          March 15, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Bill & Melinda Gates Foundation

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          04

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : As part of Iveric Bio’s lifecycle expansion plan for Zimura (avacincaptad pegol), the Company is committed to developing sustained release technologies for the treatment of age-related macular degeneration (AMD).

                          Brand Name : Zimura

                          Molecule Type : Large molecule

                          Upfront Cash : $1.2 million

                          July 05, 2022

                          Lead Product(s) : Avacincaptad Pegol

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Recipient : IVERIC bio

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Controlled release of dexamethasone eye drops, based on DelSiTech™ Silica Matrix technology, is a revolutionary eye drop product that is applied as a single drop, once daily under the eye lid which maintains therapeutic drug concentration in the eye.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 28, 2022

                          Lead Product(s) : Dexamethasone

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Recipient : Optifye Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank